tRNA Fragment Microarray for Inhibitor Screening
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for methods to identify inhibitors of protein synthesis, particularly those targeting RNA molecules with modified nucleotide bases, which are underutilized therapeutic targets for antimicrobial and anticancer treatments.
Innovation Solution
The development of methods involving the formation of mixtures with tRNA fragments containing modified nucleotides and target molecules, followed by incubation and detection of inhibitor compounds that prevent binding, along with the use of microarrays and nucleic acid molecules with modified nucleotides for high-throughput assays.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If traditional protein synthesis targets are used, then existing drugs can be applied, but therapeutic options are limited and resistance develops
Solution Approach 1:
The patent segments the tRNA molecule into specific functional domains (TΨC-loop, D-loop, anticodon stem loop) and uses these segmented regions as independent binding targets for inhibitors. This segmentation allows for the development of targeted therapies against specific bacterial protein synthesis mechanisms, expanding therapeutic options while maintaining effectiveness by avoiding cross-resistance with traditional antibiotics that target different sites.
Solution Approach 2:
The patent focuses on specific local regions of the tRNA molecule that contain modified nucleotide bases, particularly in the TΨC-loop and D-loop regions. By targeting these specific local regions with unique modification patterns that differ between bacterial and mammalian tRNA, the invention achieves selective inhibition of bacterial protein synthesis while preserving mammalian cell function, thereby expanding versatile therapeutic options with reliable effectiveness.
2Adaptability or versatility
If modified nucleotide bases in tRNA are targeted, then new therapeutic opportunities arise, but identification methods are complex and time-consuming
Solution Approach 1:
The patent employs microarrays that are pre-loaded with synthetic tRNA fragments containing specific modified nucleotide bases (such as ribothymidine, pseudouridine, and dihydrouridine) at predetermined positions. This preliminary preparation of the detection platform with known modification patterns allows for high-throughput screening of inhibitor compounds without requiring complex real-time modification analysis, thereby reducing identification methodology complexity while enabling versatile target exploration.
Solution Approach 2:
The patent uses synthetic copies of tRNA fragments with defined modification patterns that replicate the key structural and chemical features of native modified tRNA regions. These simplified copies serve as surrogate targets in microarray assays, allowing researchers to identify inhibitors that would also bind to native modified tRNA in bacterial cells, thus reducing the complexity of identification methods while maintaining the ability to discover versatile therapeutic targets.
3Productivity
If high-throughput screening is implemented, then inhibitor identification speed increases, but assay complexity and resource requirements increase
Solution Approach 1:
The patent develops a universal microarray platform that can simultaneously screen for inhibitors targeting multiple different tRNA regions (TΨC-loop, D-loop, anticodon stem loop) and multiple different modified nucleotide types using a single integrated system. This multi-functional assay platform increases inhibitor identification rate by allowing parallel screening of numerous compounds against various targets, while the standardized universal design actually reduces overall system complexity compared to running separate specialized assays for each target type.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables the identification of inhibitors that can effectively target bacterial infections and potentially cancer cells by disrupting protein synthesis, offering new therapeutic options.
Implementation Method 1
incubating the mixture under conditions that allow binding of the tRNA TΨC-loop fragment and the target molecule
Implementation Method 2
detecting whether or not the test compound inhibits the binding of the tRNA TΨC-loop fragment and the target molecule
Data Source
AI summary
Compositions and methods for identifying inhibitors of RNA-target molecule interactions are provided as well as identifying inhibitors that block the role of tRNA in protein synthesis. The methods involve forming a mixture comprising a tRNA fragment molecule containing a modified nucleotide, a target molecule capable of binding to the tRNA fragment, and a test compound. The mixture is incubated under conditions that allow binding of the tRNA and the target molecule in the absence of the test compound. Assays can then be performed that detect whether or not the test compound inhibits the binding of the tRNA molecule and the target molecule. High throughput assays are also provided.